Blincyto

Chemical Nameblinatumomab
Dosage FormInjection (intravenous; 35 mcg)
Drug ClassAntineoplastics
SystemBlood
CompanyAmgen Inc.
Approval Year2014

Indication

  • For the treatment of adults and children with B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.
  • For the treatment of adults and children with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Last updated on 4/19/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Blincyto (blinatumomab) Prescribing Information2014Amgen Inc., Thousand Oaks, California